account_id none on file
legal_name Adial Pharmaceuticals, Inc.
ticker ADIL
cik 1513525
domain adial.com
linkedin_company_url https://www.linkedin.com/company/adialpharma
entry_point_account_id none on file
name Adial Pharmaceuticals Inc
exchange Nasdaq
sector Health Care
hq Charlottesville, VA, United States
sector index/company/sector/health-care/
calls 0 filings 15 executives 8 family 0
why_nownone on file
callsnone on file
filings
This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies and intermediaries.
filing / Aug 24, 2026 / receipt
The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the Acquisition and the Transactions.
filing / Aug 24, 2026 / receipt
(“Adovate”), in which the Company holds a significant equity stake, for sharing of the efforts of certain Adovate employee time and use of Adovate office space and equipment, and for the sharing of efforts of certain of our employees.
filing / Aug 24, 2026 / receipt
Cary J. Claiborne, Chief Executive Officer, President, and Director
filing / Aug 24, 2026 / receipt
Robertson H. Gilliland, MBA, Director
filing / Aug 24, 2026 / receipt
Kevin Schuyler, CFA, Chairman of the Board of Directors, Lead Independent Director
filing / Aug 24, 2026 / receipt
Kevin Schuyler has served as our non -executive Chairman of the Board since August 2022
filing / Aug 24, 2026 / receipt
Matthew Davidson, Ph.D. was appointed to our Board of Directors as a Class I director and as our Chief Development Officer effective immediately after the effective time of the Merger on June 11, 2026
filing / Aug 24, 2026 / receipt
Class III Directors J. Kermit Anderson, Director
filing / Aug 24, 2026 / receipt
Kevin Schuyler serves as our Nonexecutive Chairman of the Board and also as our Lead Independent Director.
filing / Aug 24, 2026 / receipt
Our Board of Directors consists of six members: J. Kermit Anderson, Robertson H. Gilliland, Kevin Schuyler, Cary J. Claiborne, Matthew Davidson, Ph.D. and Wendy B. Young, Ph.D.
filing / Aug 24, 2026 / receipt
Vinay Shah became our Chief Financial Officer in November 2024.
filing / Aug 24, 2026 / receipt
executives
| Cary J. Claiborne | President | - | receipt |
| J. Kermit Anderson | Director | - | receipt |
| Kevin Schuyler | Nonexecutive Chairman of the Board | - | receipt |
| Matthew Davidson, Ph.D. | Director | - | receipt |
| Robertson H. Gilliland | Director | - | receipt |
| Tony Goodman | Chief Operating Officer | - | receipt |
| Vinay Shah | Chief Financial Officer | receipt | |
| Wendy B. Young | Director | - | receipt |
familynone on file
upcoming
| 2026-11-12 | earnings call | scheduled | ir |
changes
| 2024-11-05 | Chief Financial Officer, appointed | sec_8k |
| 2022-08-23 | director, appointed | sec_8k |
| 2022-08-23 | President and Chief Executive Officer, appointed | sec_8k |
| 2021-12-09 | Chief Operating Officer, appointed | sec_8k |
mcp_package_hint
slug adial-pharmaceuticals-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$